Q&A with Genentech CEO Alexander Hardy on Medicare’s drug price negotiations

Be­fore and af­ter it was ac­quired by Roche, Genen­tech has made a name for it­self with bi­o­log­ics — the large mol­e­cules that Con­gress re­cent­ly af­ford­ed 13 years of pro­tec­tion be­fore new price ne­go­ti­a­tions can kick in from Medicare.

The ex­panse of those ne­go­ti­a­tions, and how they’re about to be im­ple­ment­ed, is of para­mount fo­cus for bio­phar­ma ex­ec­u­tives look­ing to shape any changes and stay ahead of the shift­ing land­scape. Genen­tech CEO Alexan­der Hardy spoke to End­points News late last week about every­thing from how he sees the new law hit­ting his com­pa­ny to what he’s telling Con­gress. See be­low a slight­ly short­ened tran­script of our Q&A.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN